

Press release

Subscription carried out of Elos Convertibles 2008/2011

- SEK 13,920,000 issue amount
- 185,600 convertibles
- SEK 75 per convertible
- 4.45 percent interest on convertibles

Elos AB's (formerly AB Westergyllen) Annual General Meeting on April 28, 2008 resolved to approve the Board's decision to assume a convertible debenture loan in a maximum nominal amount of SEK 16,000,000, which could be converted to Series B shares, through the issue of not more than 200,000 convertibles, with a term from July 1, 2008 through June 30, 2011.

The right to subscribe convertibles, with waiver of the shareholders' preferential rights, accrues to persons permanently employed in Elos AB or its Swedish subsidiaries or hold similar employment status in any of Elos AB's foreign subsidiaries at expiration of the subscription period on May 30, 2008 and who at that date has not resigned or has been given notice of termination of their employment. Entitlement to subscribe is also granted to those who not later than during the subscription period has reached an agreement on permanent employment in Elos AB or its Swedish subsidiaries or similar employment status in any of Elos AB's foreign subsidiaries. Application to subscribe was carried out during the period May 19 through May 30, 2008.

Employees within the Elos Group have subscribed for Elos Convertibles 2008/2011 totalling SEK 13,920,000, corresponding to 185,600 convertibles at a conversion price of SEK 75. Allotment was in accordance with subscription applications. If all convertibles are converted to shares, the dilution would be 3.1 percent of the share capital and 1.2 percent of the number of votes, based on the number of registered shares today. The interest on the convertibles is set at 4.45 percent.

Each convertible can, during the period May 1 through June 15, 2011, be converted to one Series B share in Elos AB.

Lidköping 2008 06 10

Elos AB (publ)

For further information, contact Karin Edholm, CFO, +46 510 48 43 64, +46 73 274 52 92.

Elos' operations comprise development, manufacturing and marketing to international customers who need complex products used in demanding environments within the Medical Technology and Precision Technology business areas. For additional information, visit www.elos.se.

The information of this press release is of the kind that Elos AB has to make public according to the law of the securities market and/or the law of trade by financial instruments.
The information was made public on June 10, 2008 at 10.00 (CET).